466 related articles for article (PubMed ID: 22208546)
1. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
Ballmann M; Smyth A; Geller DE
Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
[TBL] [Abstract][Full Text] [Related]
2. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?
Lo D; VanDevanter DR; Flume P; Smyth A
Respir Med; 2011 Dec; 105 Suppl 2():S9-17. PubMed ID: 22208548
[TBL] [Abstract][Full Text] [Related]
3. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
Elborn JS; Henig NR
Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
[TBL] [Abstract][Full Text] [Related]
4. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
[TBL] [Abstract][Full Text] [Related]
5. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
6. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
Hansen C; Skov M
Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
[TBL] [Abstract][Full Text] [Related]
7. Aerosolized antibiotics in cystic fibrosis: an update.
Fiel SB
Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
[TBL] [Abstract][Full Text] [Related]
8. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Assael BM
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
[TBL] [Abstract][Full Text] [Related]
9. [Inhaled antibiotic therapy in cystic fibrosis].
Girón Moreno RM; Salcedo Posadas A; Mar Gómez-Punter R
Arch Bronconeumol; 2011 Jun; 47 Suppl 6():14-8. PubMed ID: 21703474
[TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
[TBL] [Abstract][Full Text] [Related]
11. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
Pesaturo KA; Horton ER; Belliveau P
Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
[TBL] [Abstract][Full Text] [Related]
12. Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis.
VanDevanter DR; Ballmann M; Flume PA
Respir Med; 2011 Dec; 105 Suppl 2():S18-23. PubMed ID: 22208544
[TBL] [Abstract][Full Text] [Related]
13. Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2010 Aug; 4(4):435-44. PubMed ID: 20658904
[TBL] [Abstract][Full Text] [Related]
14. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
15. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
Ramsey BW; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Kravitz RM; Schidlow DV; Wilmott RW; Astley SJ; McBurnie MA
N Engl J Med; 1993 Jun; 328(24):1740-6. PubMed ID: 8497284
[TBL] [Abstract][Full Text] [Related]
17. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
Antonela Antoniu S
Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
[TBL] [Abstract][Full Text] [Related]
18. The approach to Pseudomonas aeruginosa in cystic fibrosis.
Bendiak GN; Ratjen F
Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
[TBL] [Abstract][Full Text] [Related]
19. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
20. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
